- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Aditya Birla Sun Life Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.34 | 1.94 |
NAV | ₹30.32 | ₹37.84 |
Fund Started | 20 Jun 2019 | 25 Jun 2018 |
Fund Size | ₹814.95 Cr | ₹4914.64 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.34
1.94
NAV
₹30.32
₹37.84
Fund Started
20 Jun 2019
25 Jun 2018
Fund Size
₹814.95 Cr
₹4914.64 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 16.75% | 24.88% |
3 Year | 18.49% | 24.25% |
5 Year | 19.72% | 25.39% |
1 Year
16.75%
24.88%
3 Year
18.49%
24.25%
5 Year
19.72%
25.39%
Holding Analysis
Equity | 98.79% | 98.28% |
Cash | 1.21% | 1.72% |
Equity
98.79%
98.28%
Cash
1.21%
1.72%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 14.61% |
Cipla Ltd. | 8.44% |
Torrent Pharmaceuticals Ltd. | 7.05% |
Apollo Hospitals Enterprise Ltd. | 6.90% |
Abbott India Ltd. | 6.14% |
Lupin Ltd. | 4.88% |
Aurobindo Pharma Ltd. | 4.86% |
Fortis Healthcare Ltd. | 4.52% |
Ajanta Pharma Ltd. | 4.16% |
Ipca Laboratories Ltd. | 4.06% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Fund Manager
Name | Dhaval Joshi | Dharmesh Kakkad |
Start Date | 21 Nov 2022 | 23 Feb 2021 |
Name
Dhaval Joshi
Dharmesh Kakkad
Start Date
21 Nov 2022
23 Feb 2021
About Fund
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Jun 2019 | 25 Jun 2018 |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Jun 2019
25 Jun 2018